Quantcast

Latest Edith Perez Stories

2012-12-10 12:22:29

Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in about 25 percent of patients – and oncologists haven't been able to identify these women before treatment. This situation may soon change, according to a Mayo Clinic study being presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. A team of U.S....

2011-12-09 16:26:04

Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient's outcome after treatment for HER2-Positive Breast Cancer with Herceptin, say Mayo Clinic researchers. HER2-positive breast cancer gets its name from a protein called human epidermal growth factor receptor 2 that promotes cancer cell growth. The finding, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium,...

2011-06-06 12:52:41

ASCO Abstract #10504. Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group (NCCTG) investigators. The study, which looked at tumors from 1,802 patients enrolled in the NCCTG N9831 clinical trial, found that patients with HER2-positive breast cancer and had either a loss of PTEN functioning or normal PTEN activity...

2010-12-13 07:52:37

Results for testing breast tumors for HER2 (http://www.mayoclinic.com/health/breast-cancer/AN00495) proteins and genes is most often straightforward when one piece of tumor (a single tumor block) is analyzed. However, tumors can be diverse, and researchers at Mayo Clinic (http://www.mayoclinic.org/) found that HER2 results can vary in up to 10 percent of patients when several tumor blocks are analyzed. This could have significant implications for patient treatment, say the researchers, who...

2010-09-20 16:55:00

SAN MATEO, Calif., Sept. 20 /PRNewswire-FirstCall/ -- Con-way Inc. (NYSE: CNW) announced that Edith R. Perez has been named to the Board of Directors. The appointment is effective immediately. (Logo: http://photos.prnewswire.com/prnh/20060418/SFTU007LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20060418/SFTU007LOGO) Ms. Perez has been with the law firm of Latham & Watkins, LLP for more than 25 years, is a partner in the firm's Los Angeles office and is a member of its Finance...

2009-12-12 12:03:58

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin. Patients using Herceptin and chemotherapy at the same time had a relative 25 percent reduction in the risk of recurrence of cancer or death, compared with women who used Herceptin after chemotherapy, says Edith Perez,...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related